Skip to main content
Premium Trial:

Request an Annual Quote

Baron Frederick Charles von Nidda, John Newton

Premium

DNA-security company Applied DNA Sciences this week said it has opened a marketing and sales office in London, and appointed

Baron Frederick Charles von Nidda

as general manager.

Von Nidda, a partner in the European-advisory firm GA Associates, has recently helped with the finance and expansion of a number of independent businesses, including the engineering firm Minimould, the pharma company Res-Del International, the medical firm Clinical Research Centres International; and the media concern Tri-Continental Films.


Gene Logic of Gaithersburg, Md., today announced the completion of its $52 million acquisition of TherImmune Research.

Gene Logic paid TherImmune shareholders approximately $30.9 million in cash, and issued 4 million shares of common stock, with a value of approximately $21.2 million, based on the closing price of its stock.

The company announced the acquisition in February.


The UK Biobank has appointed as CEO John Newton, a consultant in epidemiology at University of Oxford’s unit of health care epidemiology.

The UK Biobank funders are composed of the Medical Research Council, the Wellcome Trust, and the UK Department of Health.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.